

# ITALIAN SUMMIT ON PRECISION MEDICINE

*Presidents: Giuseppe Curigliano and Paolo Marchetti*

13 - 14 November, 2021

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome

Foto: Oreste Fiorenza

**Fmp**  
Fondazione per la  
Medicina Personalizzata

## Rational

Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics. Detailed genomic screening is likely to play a central role in this.

Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patient-sized medical intervention. Personalized medicine promoters usually highlight its potential to combine a more effective health-care with costs containment, according to the following rules:

monitoring of disease risks and more effective prevention;

- early intervention;
- selection of optimal therapy;
- reduction of trial-and-error prescribing and reduction of adverse drug reactions;
- exclusion of unnecessary drugs;
- therapeutic drug monitoring and disease progression/remission monitoring;
- increased patient compliance with therapy.

But, in spite of expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each Country. Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.

The aim of the meeting is to discuss with key opinion leader about the future prospective of Precision Medicine and Precision Oncology and the application in the real world.

## Saturday, 13<sup>th</sup> November, 2021

<b>09.00</b>	Event opens for registration and coffee
<b>09.30</b>	Opening <i>talks</i> Precision medicine for colorectal cancer - <b>Alberto Bardelli</b>
<b>10.00 - 10.30</b>	Clinical validity and clinical utility of NGC: the value of ESCAT scale - <b>Joaquin Mateo</b>
<b>10.30 - 11.00</b>	Clinical-molecular databases of matched targeted agents and standardized reports of next-generation sequencing tests - <b>Rodrigo Dienstmann</b>
<b>11.00 - 11.30</b>	Implementing precision medicine in cancer care - <b>Christophe Le Tourneau</b>
<b>11.30 - 12.00</b>	Clinical validity of NGS and innovation in clinical diagnosis - <b>Jeffrey Ross</b>
<b>12.00 - 13.00</b>	Lunch  <i>Validated drivers and genomic landscape of solid tumors from private to common genomic alterations</i> <b>Chair: Paolo Marchetti</b>
<b>13.00 - 13.20</b>	Lung cancer - <b>Justin Gainor</b>
<b>13.20 - 13.50</b>	Gastrointestinal cancer - <b>Emil Voest</b>
<b>13.50 - 14.10</b>	Carcinoma of Unknown primary: Missing primary or missing biology - <b>George Pentheroudakis</b>
<b>14.10 - 14.30</b>	Molecular and immunological landscape in melanoma - <b>Paolo Ascierto</b>
<b>14.30 - 14.50</b>	Integrative analyses to identify genetic determinants of immune responsiveness in cancer - <b>Jan Haanen</b>
<b>14.50 - 15.10</b>	Breast cancer - <b>Philippe Aphantimos</b>
<b>15.10 - 15.40</b>	Coffee break  <i>Tumor DNA in tissue and blood</i> <b>Chair: Giuseppe Curigliano</b>
<b>15.40 - 16.00</b>	Comprehensive genomic profiling in tumor analysis - <b>Jeffrey Ross</b>
<b>16.00 - 16.20</b>	Liquid biopsy in daily clinical practice - <b>Nicola Normanno</b>
<b>16.20 - 16.40</b>	Precision medicine in cancer care - <b>Alexander Drilon</b>
<b>16.40 - 17.10</b>	Q & A and wrap up session - <b>Giuseppe Curigliano</b>

## Sunday, 14<sup>th</sup> November, 2021

### *Clinical trials in the era of genomic medicine*

**Chair: Gabriella Pravettoni**

- 09.00 - 09.20** Complexity of computational analysis of genome sequencing and reporting - **Matteo Repetto**
- 09.20 - 09.40** Liquid biopsy and comprehensive genomic profiling - **Dean Pavlick**
- 09.40 - 10.00** Clinical trials in the era of genomic medicine - **Christophe Massard**
- 10.00 - 10.20** Precision medicine: challenges and opportunities in the era of big data - **Lisa Licitra**
- 10.20 - 10.30** Q&A
- 10.30 - 11.00** Coffee break

### *Regulatory challenges in the era of personalized medicine*

**Chair: Giuseppe Curigliano, Gabriella Pravettoni and Paolo Marchetti**

- 11.00 - 11.30** Perspective on drug approval process in the era of precision medicine - **Jorge Camarero**
- 11.30 - 12.00** Sustainability of cancer care, in precision medicine: value for money and sustainability issues - **Claudio Jommi**
- 12.00 - 12.30** Understanding cognitive processes of patients behind genetic testing report - **Gabriella Pravettoni**
- 12.30 - 13.00** Q&A
- 13.00 - 13.45** Lunch
- 13.45 - 14.10** Implementing precision medicine in real life - **Paolo Marchetti**
- 14.10 - 15.00** Panel discussion (Interactive discussion with audience) **Paolo Marchetti and Giuseppe Curigliano**
- 15.00 - 16.00** *Statements and outline of the manuscript*
- 16.00 - 16.30** Final CME Test

## General Information

**Presidents: Giuseppe Curigliano and Paolo Marchetti**

**Scientific Secretary: Andrea Botticelli**

### **Congress Venue:**

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome

CME Provider n. 4795

Didactika S.r.l.

Piazza della Trasfigurazione, 8/a - 00151 Rome

ref. n. 328805

CME Credits: 13

This event is open to biologists, medical doctors and surgeons

### **Disciplines:**

Dermatology, Haematology, Gastroenterology, Internal medicine, Oncology, Radiotherapy, Gynaecology, Histology, Biochemistry, Pharmacology and Clinical Toxicology, Clinical Pathology.

To obtain the CME credits, the participant should be present for at least 80% of the total duration of the congress, fill in all the forms and pass the final CME test. At the end of the congress, the organizing secretariat will issue a certificate of attendance.

### **Registration:**

Registration is free. To register for the Congress, please visit us at [www.didactika.it](http://www.didactika.it) or send an e-mail to: [info@didactika.it](mailto:info@didactika.it)

### **Registration includes:**

Web access to all scientific sessions. Certificate of attendance.

This congress will be held in presence for a maximum of 50 participants and on web using the following link:

[https://cst-cicarelli-it.zoom.us/webinar/register/WN\\_4NvAarVDTeuZiBLgrGPKmA](https://cst-cicarelli-it.zoom.us/webinar/register/WN_4NvAarVDTeuZiBLgrGPKmA)

**Philippe Aftimos** - Clinical Trials Conduct Unit (CTCU) – Institut Jules Bordet, Université Libre de Bruxelles, Brussels Belgium

**Paolo A. Ascierto, MD** - Melanoma. Cancer Immunotherapy and Development Therapeutics Unit  
Istituto Nazionale Tumori IRCCS Fondazione «G. Pascale», Naples Italy

**Alberto Bardelli, PhD** - Professor, Dept of Oncology, University of Turin - Candiolo Cancer Institute FPO-IRCCS, Turin Italy

**Jorge Camarero, PhD** - Vice President, Technical Regulatory & Access Parexel International, Las Rozas de Madrid Spain

**Giuseppe Curigliano, MD** - Clinical Director, Division of Early Drug Development for Innovative Therapy Co-Chair Cancer Experimental Therapeutics Program Department of Oncology and Hemato-Oncology University of Milan European Institute of Oncology, Milan Italy

**Rodrigo Dienstmann, MD** - Oncology Data Science (ODysSey) Group Vall d’Hebron Institute of Oncology, Barcelona Spain

**Alexander Drilon, MD** - Chief, Early Drug Development Service Associate Attending Physician, Thoracic Oncology Service Memorial Sloan Kettering Cancer Center, New York USA

**Justin Gainor, MD** - Director, Center for Thoracic Cancers Director of Targeted Immunotherapy; Associate Professor of Medicine at Harvard Medical School, Boston MA USA

**John B.A.G. Haanen** - Department Medical Oncology, the Netherlands Cancer Institute, Amsterdam The Netherlands

**Claudio Jommi MSc** - Professor of Practice di Health Policy, SDA Bocconi

**Christophe Le Tourneau, MD PhD** - Head of Department of Drug Development & Innovation (D3i) Institut Curie – Paris & Saint-Cloud, Professor of Medicine Paris-Saclay University INSERM U900 Research unit, Paris France

**Lisa Licitra** - Director of Medical Oncology Head and Neck Cancer Department, Istituto Nazionale Tumori, Milan Italy

**Paolo Marchetti, MD PhD** - Department of Clinical and Molecular Medicine Sapienza University of Rome, President of FMP - Foundation of Personalized Medicine, Professor of Oncology Sapienza University of Rome Italy

**Christophe Massard** - Gustave Roussy and Université Paris-Saclay, France

**Joaquin Mateo, MD PhD** - Group Leader Prostate Cancer Translational Research Vall Hebron Institute of Oncology (VHIO) Barcelona Spain

**Nicola Normanno** - Chief Scientific Officer IRCCS Fondazione Pascale, Head of Department IRCCS Fondazione Pascale, President QN Path, President SIC, Naples Italy

**Dean Pavlick** - Scientist II Cancer Genomics Research Foundation Medicine, Cambridge, MA USA

**Gabriella Pravettoni, PhD** - Full Professor of Cognitive Psychology, Director - Department of Oncology and Hemato-Oncology - University of Milan, Director - Psycho-Oncology Division - European Institute of Oncology, Milan Italy

**Matteo Repetto, MD** - Medical Oncology Resident, Division of New Drugs and Early Drug Development, Istituto Europeo di Oncologia, Milan Italy

**Jeffrey S. Ross, MD** - Medical Director Foundation Medicine, Cambridge, MA USA

**Emile Voest** - Professor of Medical Oncology, Netherlands Cancer Institute, Amsterdam The Netherlands.

Thanks to the non conditioning contribution of:

